Details of the Drug Combination

General Information of Drug Combination (ID: DCWJIQJ)

• Drug Combination Name: RTB101 + SCH-900776
• Indication: Carcinoma; Status: Investigative [1]
• Component Drugs:
  RTB101 (DM62QTW): Small molecular drug
  SCH-900776 (DM67EMK): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: MDAMB436
  Zero Interaction Potency (ZIP) Score: 1.53
  Bliss Independence Score: 1.54
  Loewe Additivity Score: 11.18
  LHighest Single Agent (HSA) Score: 13.18

Molecular Interaction Atlas of This Drug Combination

Indication(s) of RTB101

Disease Entry	ICD 11	Status	REF
Respiratory tract infection	CA45	Phase 3	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]

RTB101 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
CREB-regulated transcription coactivator 1 (TORC1)	TT4GO0F	CRTC1_HUMAN	Inhibitor	[5]

Indication(s) of SCH-900776

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]

SCH-900776 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[6]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour	DCLNLE2	ES2	Investigative	[7]
Breast and ovarian cancer syndrome	DCJTRP0	UWB1289	Investigative	[1]
Breast and ovarian cancer syndrome	DCMMMHJ	UWB1289+BRCA1	Investigative	[1]
Carcinoma	DCXS7DH	OV90	Investigative	[1]
Colon carcinoma	DC0AU7S	RKO	Investigative	[1]
Adenocarcinoma	DC2AJYS	OVCAR3	Investigative	[8]
Adenocarcinoma	DCAVLNZ	A427	Investigative	[8]
Adenocarcinoma	DCYMZHV	NCIH2122	Investigative	[8]
Adenocarcinoma	DCN0Q5D	NCIH23	Investigative	[8]
Adenocarcinoma	DCKA5NH	NCIH520	Investigative	[8]
Adenocarcinoma	DC2QPIS	COLO320DM	Investigative	[8]
Adenocarcinoma	DCFO2BC	HCT116	Investigative	[8]
Adenocarcinoma	DCDEWZD	HT29	Investigative	[8]
Amelanotic melanoma	DCTFSEU	A2058	Investigative	[8]
Germ cell tumour	DCTMSTN	PA1	Investigative	[8]
Large cell lung carcinoma	DCVONCU	NCI-H460	Investigative	[8]
Malignant melanoma	DCDOI0G	A375	Investigative	[8]
Malignant melanoma	DCY2RQO	RPMI7951	Investigative	[8]
Malignant melanoma	DCOS18K	SKMEL30	Investigative	[8]
Malignant melanoma	DC4331X	UACC62	Investigative	[8]
Mesothelioma	DCYXLID	MSTO	Investigative	[8]
Non small cell carcinoma	DCJJ5G0	SKMES1	Investigative	[8]
Ovarian endometrioid adenocarcinoma	DCMI9TQ	A2780	Investigative	[8]
Ovarian serous cystadenocarcinoma	DCO053M	SK-OV-3	Investigative	[8]
Prostate carcinoma	DC8QJPQ	VCAP	Investigative	[8]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
• [2] ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7943).
• [5] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [6] Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
• [7] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [8] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976